There is a lack of up-to-date epidemiological data regarding patients with lower extremity peripheral artery disease (PAD) who underwent lower limb revascularization in France. It appears interesting to provide an estimation of the subset of patients who could benefit from the dual pathway inhibition (DPI: low-dose rivaroxaban 2.5 mg b.i.d and aspirin 100 mg o.d.) indicated for the prevention of atherothrombotic events (AE) after revascularization for PAD, following the results of the VOYAGER-PAD trial. To quantify the number of patients with PAD who annually undergo lower limb revascularization (PAD revascularized population) in France, to identify the proportion of those who could benefit from DPI and to assess the onset of AE in those two populations. Using the French Hospital Discharge Database (PMSI), patients hospitalized for revascularization for PAD (index date) were followed from January 1, 2016 to December 31, 2019. AE (a composite of: acute limb ischemia, major amputation for vascular cause, myocardial infarction, ischemic stroke/TIA, and in-hospital death) as well as comorbidities were identified using ICD-10 codes, medical procedure code, or medication dispensing. Patients eligible to DPI were defined by transposing the inclusion/exclusion criteria of the VOYAGER-PAD trial to the French PAD revascularized population. The unadjusted incidence rate of AE was assessed both populations. During the 4-year study period, a total of 191,758 patients (47,340 patients/y on average) underwent revascularization for PAD. Patients had a mean age of 72 ± 12.2 years at index date and were mainly men (69.3%). The three most frequent comorbidities were diabetes mellitus (35.7%), chronic coronary disease (30.3%), and renal failure (15.8%). A share ranging from 46.6 to 49.5% would have been eligible for DPI after revascularization. In those patients, age, gender and comorbidities distribution were similar to the PAD revascularized population. Cumulative incidence of the first AE at 12, 24 and 36 months were at 33.8%, 43.2% and 50.1% respectively in the overall population, and 25.5%, 32.8%, and 37.7% for the DPI-eligible population. This study provides a comprehensive and contemporary overview of patients treated by revascularization for PAD in our country in the recent years. Adjusted comparative results will allow to compare these occurrences between the different groups of interest.